ClinicalTrials.gg
RecruitingNCT07850609EXPrESSIVE-18Updated Nov 12, 2026

A Clinical Study of Alimatravir (MK-8527) in Transgender (Trans) and Gender Diverse Individuals on Gender-affirming Hormone Therapy and at Low Likelihood of Human Immunodeficiency Virus (HIV)-1 Exposure (MK-8527-018)

A Phase 2 interventional study of Alimatravir in HIV, sponsored by Merck Sharp & Dohme LLC. Recruiting at 7 sites in 2 countries. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Prevention

Updated Nov 12, 2026Now RecruitingFirst sites in Canada and United States+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
80
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this study is to learn about the safety of alimatravir (MK-8527) in transgender and gender-diverse people and if they tolerate it.

02

Conditions studied

  • HIV

Keywords

  • Prophylaxis
03

In context

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The main inclusion criteria include but are not limited to the following:

  • Is confirmed (HIV)-uninfected
  • Is a transgender or gender diverse (TGD) person, ie, a person whose gender identity differs from the sex that was assigned at birth
  • Is on stable gender-affirming hormone therapy (GAHT) and does not intend to change therapy through 2 months after the last dose of study intervention
  • Has a low likelihood of HIV exposure

Exclusion criteria

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

  • Has evidence of acute or chronic infection
  • Has a history of within 5 years of Screening, except for adequately treated basal cell or squamous cell skin cancer, or in situ anal or cervical cancers
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Alimatravir

    Alimatravir 11 mg will be taken once monthly (qm)

    Drug: Alimatravir

Interventions

  • 11 mg tablets taken orally once monthly (qm) for a total of 3 doses

    Also known as: MK-8527

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Experience an Adverse Event (AE)

    An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experience an AE will be reported.

    Time frame: Up to approximately 4 months

  2. Number of Participants Who Discontinue Study Treatment Due to an AE

    An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who discontinue study treatment due to an AE will be reported.

    Time frame: Up to approximately 2 months

Secondary outcomes

  1. Maximum Plasma Concentration (Cmax) of Alimatravir in Plasma

    Plasma samples will be collected to determine the Cmax of alimatravir.

    Time frame: At designated time points (up to approximately 3 months)

  2. Time to Maximum Plasma Concentration (Tmax) of Alimatravir in Plasma

    Plasma samples will be collected to determine the Tmax of alimatravir.

    Time frame: At designated time points (up to approximately 3 months)

  3. Plasma Trough Concentration (Ctrough) of Alimatravir

    Plasma samples will be collected to determine the Ctrough of alimatravir.

    Time frame: At designated time points (up to approximately 3 months)

  4. Plasma Estradiol Concentration

    Blood samples will be collected to determine the plasma concentration of estradiol.

    Time frame: Up to approximately 6.5 months

  5. Plasma Testosterone Concentration

    Blood samples will be collected to determine the plasma concentration of testosterone.

    Time frame: Up to approximately 6.5 months

  6. Plasma Dihydrotestosterone Concentration

    Blood samples will be collected to determine the plasma concentration of dihydrotestosterone.

    Time frame: Up to approximately 6.5 months

07

Study locations

7 of 7 sites recruiting
  • Bridge HIV - San Francisco Department of Public Health ( Site 0002)
    San Francisco, California 94102, United States
    Recruiting
    • Study Coordinator · Contact628-217-7400
  • Whitman-Walker Institute ( Site 0008)
    Washington D.C., District of Columbia 20032, United States
    Recruiting
    • Study Coordinator · Contact202-207-2510
  • Fenway Health ( Site 0004)
    Boston, Massachusetts 02215, United States
    Recruiting
    • Study Coordinator · Contact617-927-6400
  • Mazzoni Center ( Site 0010)
    Philadelphia, Pennsylvania 19147, United States
    Recruiting
    • Study Coordinator · Contact215-563-0652
  • Maple Leaf Research ( Site 0102)
    Toronto, Ontario M5G 1K2, Canada
    Recruiting
    • Study Coordinator · Contact4164657936
  • Clinique de médecine Urbaine du Quartier Latin ( Site 0101)
    Montreal, Quebec H2L 4E9, Canada
    Recruiting
    • Study Coordinator · Contact5142855500
  • Gestion clinique médicale l'Actuel ( Site 0100)
    Montreal, Quebec H2L 4P9, Canada
    Recruiting
    • Study Coordinator · Contact5145241001
08

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2026 (actual). Primary completion is estimated for Dec 2027, 13 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2026
First posted
Sep 30, 2026
StartActual
Oct 27, 2026
Primary completionEst.
Dec 2, 2027
CompletionEst.
Dec 2, 2027
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 12, 2026
Sites
7 sites added — first sites in Canada and United States
Show 7 added (4 United States, 3 Canada)
  • Bridge HIV - San Francisco Department of Public Health ( Site 0002) · San Francisco, United States
  • Whitman-Walker Institute ( Site 0008) · Washington D.C., United States
  • Fenway Health ( Site 0004) · Boston, United States
  • Mazzoni Center ( Site 0010) · Philadelphia, United States
  • Maple Leaf Research ( Site 0102) · Toronto, Canada
  • Clinique de médecine Urbaine du Quartier Latin ( Site 0101) · Montreal, Canada
  • Gestion clinique médicale l'Actuel ( Site 0100) · Montreal, Canada
Nov 12, 2026
Start date
Oct 29, 2026→Oct 27, 2026 (actual)
Nov 12, 2026
Contact
Study contact now listed: added T•••@msd.com · •••8839. See the current contact
Nov 12, 2026
Registered
First appeared on the registry
Sep 30, 2026
Show all 2 updates
  1. Nov 12, 2026
    Not yet recruiting→Recruiting
    7 sites added — first sites in Canada and United States
    Show 7 added (4 United States, 3 Canada)
    • Bridge HIV - San Francisco Department of Public Health ( Site 0002) · San Francisco, United States
    • Whitman-Walker Institute ( Site 0008) · Washington D.C., United States
    • Fenway Health ( Site 0004) · Boston, United States
    • Mazzoni Center ( Site 0010) · Philadelphia, United States
    • Maple Leaf Research ( Site 0102) · Toronto, Canada
    • Clinique de médecine Urbaine du Quartier Latin ( Site 0101) · Montreal, Canada
    • Gestion clinique médicale l'Actuel ( Site 0100) · Montreal, Canada
    Start date Oct 29, 2026→Oct 27, 2026 (now actual)
    Contact Study contact now listed: added T•••@msd.com · •••8839. See the current contact
    + 1 other change: verification date
  2. Sep 30, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07850609
Responsible party
Sponsor
First posted
Sep 30, 2026
Start date
Oct 27, 2026
Primary completion
Dec 2, 2027 (estimated)
Completion
Dec 2, 2027 (estimated)
Last update
Nov 12, 2026

Study contacts

Toll Free Number
Contact
Trialsites@MSD.com
1-888-577-8839
Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Alimatravir

Start the discussion